Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal adhesions12.02.03.006; 07.07.03.0010.000224%Not Available
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.005093%
Abdominal pain07.01.05.0020.014472%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Acidosis14.01.03.0020.000392%
Actinic keratosis23.01.06.0010.000884%Not Available
Acute abdomen07.01.06.0150.000112%Not Available
Acute leukaemia16.01.02.001; 01.10.02.0010.000112%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000616%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.001511%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.000224%Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agranulocytosis01.02.03.0010.000783%Not Available
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.0010.008742%
Anaemia macrocytic14.12.01.002; 01.03.02.0020.000168%Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.002642%
Angina unstable24.04.04.004; 02.02.02.0040.000672%Not Available
Anorectal disorder07.03.01.0010.000112%Not Available
Anterior spinal artery syndrome24.04.06.015; 17.10.01.0080.000168%Not Available
Anuria20.01.03.0020.000336%Not Available
Anxiety19.06.02.002--
Aphasia19.21.01.001; 17.02.03.0010.000783%
Arrhythmia02.03.02.0010.002765%Not Available
Arrhythmia supraventricular02.03.03.0010.000112%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene